- Research article
- Open Access
“Cold” X5 Hairlaser™ used to treat male androgenic alopecia and hair growth: an uncontrolled pilot study
© Blum et al.; licensee BioMed Central Ltd. 2014
- Received: 26 January 2013
- Accepted: 10 February 2014
- Published: 24 February 2014
Various trials have been conducted on the management and treatment of androgenic alopecia (AGA) or male pattern hair loss using a variety of laser and light sources.
For this feasibility study, the population was composed of males between the ages of 20 and 60 years who have been experiencing active hair loss within the last 12 months and the diagnosis of AGA. They also had a Norwood-Hamilton classification of 3, 3A, 3 V, 4, 4A, or 5 for the hair thinning patterns and skin type I, II, III, or IV on the Fitzpatrick skin type scale. This two-arm randomized, parallel group study design employed stratifying randomization to balance treatment assignment within three investigational centers with at least 2 subjects enrolled in each Fitzpatrick skin type.
A statistically significant positive trend in hair growth was observed from this pilot study, to evaluate the efficacy of the novel cold X5 hairlaser device for treating male androgenic alopecia. From the repeated measures analysis of variance, difference in mean hair counts over time was statistically significant (F = 7.70; p-value < 0.0001). Subsequent, linear regression of mean hair counts at each time point was performed, and post-hoc analysis found an increasing trend of hair growth over time that was statistically significant (p-value < 0.0001) with the estimated slope of 1.406. Increased hair counts from the baseline to the end of the 26-week period were found to be strongly significant (p-value = 0.0003).
Albeit, sham device failure and resultant missing data from the control group, the positive trend hair growth, was observed due to the chronic use of X5hairlaser device. This positive benefit while in full agreement with other low laser hair devices requires intensive further investigation.
- Androgenic alopecia
- Distributed laser light
- Monochromatic light
- Linear regression
Epidemiology: defining androgenic alopecia
Androgenic alopecia (also known as androgenetic alopecia or alopecia androgenetica) is the most common cause of hair loss, and thinning in humans. Androgenic alopecia (AGA) affects an estimated 50 million men and 30 million women in the United States. Genetic predisposition to hereditary hair loss can be inherited from either side of a person’s family or both parents. It is found in men and women of all races and ethnicities. By age 40, forty percent of women and nearly forty percent of men have visible symptoms of hereditary hair loss. By age 50, fifty percent of both genders show signs of the condition. Hair loss is a common and distressing condition. Americans are expected to spend about one billion dollars annually for treatments to combat and cover up hair loss[2, 3].
It is well known that both Finasteride® and Minoxidil® are effective treatment methods, but patients who exhibit a poor response to these methods have no additional adequate treatment modalities[4, 5]. In this regard, Kim et al. reported that after 24 weeks of treatment, a low-level light therapy LLLT group showed significantly greater hair density than the sham device group. In addition Leavitt et al. reported that the HairMax LaserComb treatment group showed a significantly greater increase in mean terminal hair density than subjects in the sham device group (p < 0.0001). Moreover, significant improvements in overall hair regrowth were demonstrated in terms of patients' subjective assessment (p < 0.015) at 26 weeks when compared to baseline.
Variants appear in both men and women. However, AGA is also commonly known as male pattern baldness. In males’ classic pattern baldness, hair is lost in a well-defined pattern, beginning above both temples. Hair also thins at the crown of the head. Often a rim of hair around the sides and rear of the head is left. This pattern is dubbed "Hippocratic balding" and may rarely progress to complete baldness. Women do not suffer classic male pattern baldness, instead the hair becomes thinner around the whole scalp, and the hairline does not recede. This is dubbed "female pattern baldness" and may occur in males. This variety of AGA in women rarely leads to total baldness[1, 8].
More than 95 percent of hair loss in men is caused by AGA. Male pattern baldness is considered a genetic condition, inherited from either the mother or the father's side of the family. However, male pattern baldness also requires the presence of the male hormone testosterone. Genetics cause hair follicles to become sensitive to dihydrotestosterone (DHT), a byproduct of testosterone. The follicles begin to grow smaller, have a shorter life span and eventually fall out altogether or leave behind fuzz.
Various genetic (and possibly environmental-epigenetic) factors apparently play a role in AGA. Although researchers have long studied the factors that may contribute to this condition, many remain unknown.
Recently the existing theories have been challenged on the ground that while the androgens in question are responsible for hair growth on the face and all over the body of men, hair loss only occurs at the top of the scalp. For example, it has been suggested that AGA is a consequence of the anabolic effect of androgens such as hormonal changes leading to structural changes in skin and scalp which in turn cause hair loss. It should be noted, however, that there are as of yet no experiments testing this hypothesis.
The genetic and hormonal component of male pattern baldness
Much research concerns the genetic component of male pattern baldness, or AGA research indicates that susceptibility to premature male pattern baldness is largely X –linked, which means it is linked to genes on an X-chromosome. Other genes that are not sex linked are also involved. Men whose fathers had experienced hair loss, were 2.5 times more likely to experience hair loss themselves, regardless of the mother's side of the family[11, 12]. Large studies in 2005 and 2007 stress the importance of the maternal line in the inheritance of male pattern baldness. German researchers name the androgen receptor gene as a necessary condition for balding. They concluded that a specific variant of the androgen receptor is needed for AGA to develop. This study has been confirmed by other researchers. The androgen receptor gene is recessive. Thus, a female would need two X chromosomes with the defect to show typical male pattern alopecia. Since androgens and their interaction with the androgen receptor are the cause of AGA, the androgen receptor gene plays an important part in its development. There is a plethora of research concerning the role of genes and hormones in the development of male androgenic alopecia and reviewed elsewhere[14–22]. Studies on hormonal imbalance have also been well documented in the literature including concepts involving inhibition of 5-alpha- reductase.
Description of X5 hairlaser
The X5 HairLaser incorporates a colored LCD display that displays the precise elapsed time of the treatment session, as well as the battery power remaining and the charging status of the unit. The X5 HairLaser device is operated by; turning it on, holding the device against the scalp for approximately 15 seconds, then moving it slightly, to a different position on the head. The device is repositioned every 15 seconds in a clockwise or counterclockwise direction. After 10–15 minutes, the session is complete once all of the target areas of the scalp have been given significant exposure to low-level laser light.
Based on the literature to date we decided to systematically test the “Cold” X5 Hairlaser™ as a laser device known to deliver distributed laser light to the scalp for stimulating hair growth in men diagnosed with AGA.
This feasibility study was designed to evaluate the efficacy of the X5 HairLaser, a hand-held, low-level laser device, for the stimulation of hair growth. This study of the X5 HairLaser intended to increase terminal hair growth in males with AGA, was a multi-center, randomized, placebo-controlled study conducted at three sites in the United States. The trial was provided a clinical protocol number by ClinicalTrials.gov Protocol Registration System number NCTO2O67260.
In this pilot study we relied on the American Academy of Dermatology for hair loss guidelines as part of the inclusion criteria for enrolled patients. The participants who met all entry criteria were randomized in a 2:1 fashion to receive treatment with either the X5 HairLaser or an identical sham device that does not emit laser light. The study population was composed of males between the ages of 20 and 60 years with diagnosis of AGA who had been experiencing active hair loss within the past 12 months. They were also required to have a Norwood-Hamilton classification of 3, 3A, 3 V, 4, 4A, or 5 for the hair thinning patterns and have the skin type I, II, III, or IV on the Fitzpatrick skin type scale (see Inclusion and Exclusion Criteria below). The study was approved by Institution Review Boards (IRB) of the three selected sites. Each subject filled out an approved consent form. Specifically, the IRB was Biomedical Research Alliance of New York (BRANY), 1981 Marcus Avenue Suite 210, Lake Success, New York 11042 (file number 08-02-31-161). The three research locations are listed below the IRB covered all of them: 1) NYU School of Medicine 560 First Avenue, Room 158 New York, NY 10016; (2) Burke Pharmaceutical Research 3633 Central Avenue Suite I, Hot Springs, AR 71913; (3) Hilltop Research 6699 13th Avenue N, St. Petersburg, FL 33710.
Male with Androgenic Alopecia.
Active hair loss within the last 12 months.
Good general health.
Norwood-Hamilton classification of 3, 3A, 3V, 4, 4A or 5.
Skin Type I, II, III, or IV on the Fitzpatrick Skin Type Scale.
Has not started any new vitamins or nutritional supplements.
Continued normal grooming habits.
Adhering to scheduled office visits in a timely manner.
Diagnosed according to Guidelines of the American Academy of Dermatology Association.
Subject must have miniaturized hair present in the target area.
Subject must be fluent in English.
Signed an informed consent.
Active malignancy of any type or history of any malignancy, including any malignancy in the treatment area in the past five years.
History of hypogonadism.
Subject has used phytotherapy (e.g., saw palmetto) within eight weeks prior to baseline.
Any active skin infection in the scalp area or scarring in the target area.
Photosensitivity to laser light.
Has used Accutane® in the previous year.
History of poor wound healing.
History of anticoagulant or antiplatelet use (other than aspirin ≤325 mg., QD, which is stable for three months.
Has "buzz" cut hairstyle, defined as hair cut to less than one inch in length.
Has light blond, light gray or white hair.
Has a chronic dermatological condition (eczema, psoriasis, infection, etc.) of the scalp.
Has a pacemaker.
Has had hair transplants, scalp reduction, current hair weave, or tattooing in the target area.
Has ever received radiation therapy to the scalp, or has had chemotherapy within the past year.
Has HIV infection, connective tissue disease, a thyroid condition, inflammatory bowel disease.
Has a history or evidence of drug and/or alcohol abuse within the 12 months prior to Visit 1.
History or the presence of any serious and/or chronic medical condition(s) [including psychiatric illnesses.
Has used or currently takes Minoxidil (Rogaine™) during twelve months prior to screening.
Has taken any of the following medications during the six months prior to screening:
◦ finasteride, (or any other 5á–reductase inhibitor medications),
◦ medications with anti-androgenic properties (e.g., cyproterone acetate, spironolactone, ketoconazole, flutamide, bicalutamide),
◦ topical estrogen, progesterone, tamoxifen, anabolic steroids,
◦ medications which can potentially cause hypertrichosis (e.g., cyclosporine, diazoxide, phenytoin, psoralens),
◦ oral glucocorticoids (inhaled glucocorticoids are permitted), lithium, phenothiazines.
Design and subject demographics
A two-arm randomized, parallel group design was employed for this study, stratifying the randomization to balance treatment assignment within 3 investigational centers. Additionally, in the sampling scheme, at least 2 subjects were required to be enrolled in each Fitzpatrick skin type.
A total of 143 study participants were screened on their first visit, based on the inclusion/exclusion criteria and 119 subjects (83.22%) were entered into the study. The diagnosis of male Androgenic Alopecia was made by a trained medical Dermatologist utilizing in many cases modern hair imaging techniques including trichoscan and or trichoscopy.
They were almost uniformly distributed, resulting in approximately 40 subjects enrolled at each of the 3 different study sites. Of those 119 subjects, 70 of them (58.82%) were treated with the X5 hairlaser device while others (41.18%) received the placebo. The study consisted of 5 follow-up visits for the period of 26 weeks. On each visit of the subject, some clinical measurements were taken along with the hair count data which was provided by the imaging vendor, Canfield.
The primary objective of the study was to prove the efficacy and safety of the X5 hairlaser device for treating male AGA through comparison to the control. However, due to a problem in the implementation of the proposed protocol, whereby after evaluation of the entire study the sham device unbeknown to us constituted a laser type lighting effect. This light affected subsequent analysis on this report. While we are cognizant of the impact of the loss of sham control data we decided to conduct pilot data from the treatment group only, excluding the data from the control placebo group. Hence, the focus of this report is to investigate the presence of positive hair growth in the treatment group by examining the trend in hair counts of the 70 treated subjects (viz., a sample of the Intent-to-Treat (ITT) population).
For each subject in this study, the hair counts were supposed to be taken at 6 different time points: Baseline, Week 4, Week 8, Week 14, Week 20, and Week 26. Twenty-two subjects (31.4%) from the treatment group are however missing at least one such measurement from the given dataset due to loss to follow-up or withdrawal from the study, etc. Since it is crucial to have a complete dataset for running a repeated measures analysis of variance (ANOVA) and to test any linear trend over time, data from 48 subjects who completed all study visits with 6 valid hair count measurements were analyzed first in order to confirm any positive trend in the hair growth over time (i.e., a per-protocol analysis). Then, the missing hair counts of 22 remaining subjects with the baseline and at least one valid post-baseline assessment were imputed by carrying the most recent observation from the previous visits to the missing one(s) for each subject (viz., the method of last observation carried forward (LOCF)). The analysis was conducted again on the dataset of all 70 subjects, mixed with the imputed observations.
Frequency distribution of the Norwood Hamilton classification in the treatment group ( n = 70)
We did not systematically rule out other overlapping causes of hair loss but we were confident that the subjects tested had a well-documented diagnosis of male androgenic alopecia.
Overall trend of hair growth
With an appropriate aggregation of the classes, none of the variables aforementioned including the distribution of the Fitzpatrick skin type classification and the grouped age variable was found to have a statistically significant association with one another at 5% level of significance.
Sample statistics of the hair counts from the complete data ( n = 48)
95% Confidence interval
Sample statistics of the hair counts from the mixed data ( n = 70)
95% Confidence interval
Trend of hair growth by Age group
Sample statistics of the hair counts from 3 age groups of the complete data ( n = 48)
(a) Age group: Young (40 or below) (n = 10)
95% Confidence Interval
(b) Age group: Mid (between 41 and 50 inclusive) (n = 19)
95% Confidence interval
(c) Age group: Old (between 51 to 60 inclusive) (n = 19)
95% Confidence interval
Test results for a linear trend of the hair growth for each age group
Sample size (n)
Repeated measures ANOVA
Post-hoc linear trend test
Complete data ( n = 48)
Mixed data ( n = 70)
Trend of hair growth by skin type
Sample statistics of the hair counts from 4 Fitzpatrick skin types of the complete data ( n = 48)
(a) Fitzpatrick skin type I (n = 6)
95% Confidence interval
(b) Fitzpatrick skin type II (n = 13)
95% Confidence interval
(c) Fitzpatrick skin type III (n = 15)
95% Confidence interval
(d) Fitzpatrick skin type IV (n = 14)
95% Confidence interval
Test results for a linear trend of the hair growth for each skin type
Fitzpatrick skin type
Sample size (n)
Repeated measures ANOVA
Post-hoc linear trend test
Complete data ( n = 48)
Mixed data ( n = 70)
Table 7 above summarizes the results of statistical tests to detect the mean difference of hair counts across the measurement time points by the repeated measures analysis of variance. Just like in the analysis of the age groups, the tests were performed for each of the 4 skin type groups, and once the results were found to be significant, the post-hoc analysis of a linear trend, over time was conducted. Between the complete dataset of 48 subjects and the mixed dataset of 70 subjects, the results of analysis were again largely consistent even though the imputation captured the marginal significance of the mean difference of hair counts over time for the skin type III (p-value = 0.0346). The skin type I, had the least number of subjects assigned in both cases, and it did not show any significant mean difference of hair counts nor a linear trend over time. Although not clear, it seems that the least sensitive skin type responds the best to the device for the hair growth over time. Again, low R2 values indicated the presence of large variability which cannot be accounted for by the duration of the device usage only.
While this multi-centered study was originally planned as a randomized –sham –controlled double-blinded clinical study, it was determined following the investigation as planned, that the sham device was emitting hair growth light that ruined the control data and subsequent results. However, the present results provide significant impetus to develop a better sham device and design a clinical study in a larger cohort.
With that stated, this pilot study to evaluate the efficacy of the cold X5 hairlaser device for treating male AGA resulted in a statistically significant positive trend, in hair growth. From the repeated measures analysis of variance, it was shown that the difference in mean hair counts over time is statistically significant (F = 7.70; p-value < 0.0001). Subsequently, a linear regression on the mean hair counts at each measurement time point was performed as a post-hoc analysis, and it was found that a systematically increasing trend of hair growth over time is statistically significant (p-value < 0.0001) with the estimated slope of 1.406. The increase in hair counts, at the end points, from the baseline to the end of the 26-week period, was nevertheless, found to be strongly significant (p-value = 0.0003). As stated earlier to confirm that this effect was caused by the device and not by a random chance, a more systematic comparative study should be conducted with an appropriate control.
The main limitation of this investigation is the inability to show the difference between the device and an appropriate sham control. The investigation is also limited by the size of the population studied. In future studies we intend to increase our population since this is a non-invasive procedure. However, we are encouraged that because of the stringent inclusion/exclusion criteria these potentially important results will be confirmed in necessary larger –controlled clinical trials, in the future.
The short-term safety of the device was ensured since during the 26 weeks of this study, no any clinically severe adverse events were associated with the X5 hairlaser device.
While we cannot detail the mechanism of action of the X5 (see below) the device was designed to deliver low level laser light directly to the scalp bypassing any intervening hair. The light is delivered by light tines (15 light pipes mounted on five tripods) so that the device conforms to the contour of the scalp and makes direct contact. Other devices simply direct beams into the hair and scalp at angles that cannot be precisely controlled.
Moreover, this low-level laser therapy is intended to bio-stimulate. The effects are biochemical not thermal because the low power nature of low-level laser’s, cannot cause heating damage to living tissue. Lasers are of two principal types, "hot" and "cold", and they are distinguished by the amount of peak power they deliver. "Hot" lasers deliver power up to thousands of watts. They are used in surgery because they can make an incision that is very clean with little or no bleeding and because the laser cauterizes the incision as it cuts. They are also used in surgery that requires the removal of unhealthy tissue without damaging the healthy tissue that surrounds it.
"Cold" lasers such as the X5 HairLaser produce a lower average power of 100 milliwatts or less. This is the type of laser that is used for therapeutic purposes and it is typically, although not always, pulsed. The light is on for only a fraction of a second because it is pulsed, (turned on and off) at so many pulses per second. Pulsation results in an average power output that is very low compared to the maximum or peak output. Therefore, most therapeutic lasers produce a high peak but low average power output. Therapeutic laser is low-level laser therapy (LLLT) with photochemical rather than thermal effects[25–28]. The light is either visible (red), in most cases or invisible (infrared).
Proposed mechanism of action
Energy is transferred in the form of photons. Photons are transmitted through the skin's layers (the dermis, epidermis and the subcutaneous tissue or tissue fat under the skin). Light waves in the near infrared ranges penetrate deeper than all light waves in the visible spectrum. Photons enter the tissue and are absorbed in the mitochondria and at the cell membrane. The photon energy is converted to chemical energy within the cell in the form of adenosine triphosphate (ATP). Light emitting diode (LED) in the red region and low-level laser in the near infrared region correspond well with the characteristic energy and absorption levels of the relevant components of the respiratory chain. This LED and Laser stimulation vitalizes the cell by increasing the mitochondrial ATP production.
It is believed that successful laser therapy treatment starts with the stimulation of cell functions by the laser light. Research has shown that mitochondria are sensitive to irradiation with monochromatic light. Irradiation with light at a wavelength of 650 nm enhances ATP synthesis. The increase in ATP is believed to be one of the underlying mechanisms that help to stimulate hair follicles.
Although it is difficult to ascribe an accurate mechanism of action of the “Cold” X5L, the hypothesis, that irradiation of the scalp with this hair laser device will result in a statistically significant increase in hair growth as compared to a control, is supported by the combination of mechanisms that increase both ATP production and microcirculation.
While there are number of drugs and even other techniques to induce hair follicle growth alternatives are still important[31–33]. Albeit, sham device failure and resultant missing data from the control group, the positive trend hair growth due to the chronic use of X5hairlaser device was observed. This potential positive benefit is in full agreement with other low laser hair devices and following required larger confirmatory studies should have clinical utility for treating male AGA.
The authors would like to thank Mark Kress who funded the study and is the owner of the 5XL device.
- Soni VK: Androgenic alopecia: a counterproductive outcome of the anabolic effect of androgens. Med Hypotheses. 2009, 73 (3): 420-426. 10.1016/j.mehy.2009.03.032.PubMedView ArticleGoogle Scholar
- Duverger O, Morasso MI: To grow or not to grow: hair morphogenesis and human genetic hair disorders. Semin Cell Dev Biol. 2013, S1084-9521(13)00135-3Google Scholar
- Liang B, Yang C, Zuo X, Li Y, Ding Y, Sheng Y, Zhou F, Cheng H, Zheng X, Chen G, Zhu Z, Zhu J, Fu X, Wang T, Dong Y, Duan D, Tang X, Tang H, Gao J, Sun L, Yang S, Zhang X: Genetic variants at 20p11 confer risk to androgenetic alopeciain the Chinese Han population. PLoS One. 2013, 8 (8): e71771-10.1371/journal.pone.0071771.PubMedPubMed CentralView ArticleGoogle Scholar
- Chin EY: Androgenetic alopecia (male pattern hair loss) in the United States: what treatments should primary care providers recommend?. J Am Assoc Nurs Pract. 2013, 25 (8): 395-401.Google Scholar
- Kaufman KD, Olsen EA, Whiting D, Savin R, DeVillez R, Bergfeld W, Price VH, Van Neste D, Roberts JL, Hordinsky M, Shapiro J, Binkowitz B, Gormley GJ, Finasteride Male Pattern Hair Loss Study Group: Finasteride in the treatment of men with androgenetic alopecia. J Am Acad Dermatol. 1998, 39 (4 Pt 1): 578-589.PubMedView ArticleGoogle Scholar
- Kim H, Choi JW, Kim JY, Shin JW, Lee SJ, Huh CH: Low-level light therapy for androgenetic alopecia: a 24-week, randomized, double-blind, sham device-controlled multicenter trial. Dermatol Surg. 2013, 39 (8): 1177-1183. 10.1111/dsu.12200.PubMedView ArticleGoogle Scholar
- Leavitt M, Charles G, Heyman E, Michaels D: HairMax LaserComb laser phototherapy device in the treatment of male androgenetic alopecia: a randomized, double-blind, sham device-controlled, multicentre trial. Clin Drug Invest. 2009, 29 (5): 283-292. 10.2165/00044011-200929050-00001.View ArticleGoogle Scholar
- Sehgal VN, Srivastava G, Aggarwal AK, Midha R: Hair biology and its comprehensive sequence in female pattern baldness: diagnosis and treatment modalities–Part I. Skinmed. 2013, 11 (1): 39-45.PubMedGoogle Scholar
- Sperling LC, Mezebish DS: Hair diseases. Med Clin North Am. 1998, 82 (5): 1155-1169. 10.1016/S0025-7125(05)70408-9.PubMedView ArticleGoogle Scholar
- Gao W, Kim J, Dalton JT: Pharmacokinetics and pharmacodynamics of nonsteroidal androgen receptor ligands. Pharm Res. 2006, 23 (8): 1641-1658. 10.1007/s11095-006-9024-3.PubMedPubMed CentralView ArticleGoogle Scholar
- Hillmer AM, Hanneken S, Ritzmann S, Becker T, Freudenberg J, Brockschmidt FF, Flaquer A, Freudenberg-Hua Y, Jamra RA, Metzen C, Heyn U, Schweiger N, Betz RC, Blaumeiser B, Hampe J, Schreiber S, Schulze TG, Hennies HC, Schumacher J, Propping P, Ruzicka T, Cichon S, Wienker TF, Kruse R, Nöthen MM: Genetic variation in the human androgen receptor gene is the major determinant of common early-onset androgenetic alopecia. Am J Hum Genet. 2005, 77 (1): 140-148. 10.1086/431425. doi:10.1086/431425PubMedPubMed CentralView ArticleGoogle Scholar
- Cobb JE, Zaloumis SG, Scurrah KJ, Harrap SB, Ellis JA: Evidence for two independent functional variants for androgenetic alopecia around the androgen receptor gene. Exp Dermatol. 2010, 19 (11): 1026-1028. 10.1111/j.1600-0625.2010.01132.x. doi:10.1111/j.1600-0625.2010.01132.xPubMedView ArticleGoogle Scholar
- Levy-Nissenbaum E, Bar-Natan M, Frydman M, Pras E: Confirmation of the association between male pattern baldness and the androgen receptor gene. Eur J Dermatol. 2005, 15 (5): 339-340. PMID 16172040PubMedGoogle Scholar
- Prodi DA, Pirastu N, Maninchedda G, Sassu A, Picciau A, Palmas MA, Mossa A, Persico I, Adamo M, Angius A, Pirastu M: EDA2R is associated with androgenetic alopecia. J Invest Dermatol. 2008, 128 (9): 2268-2270. 10.1038/jid.2008.60.PubMedView ArticleGoogle Scholar
- Ellis JA, Scurrah KJ, Cobb JE, Zaloumis SG, Duncan AE, Harrap SB: Baldness and the androgen receptor: the AR polyglycine repeat polymorphism does not confer susceptibility to androgenetic alopecia. Hum Genet. 2007, 121 (3–4): 451-457.PubMedView ArticleGoogle Scholar
- Hillmer AM, Flaquer A, Hanneken S, Eigelshoven S, Kortüm AK, Brockschmidt FF, Golla A, Metzen C, Thiele H, Kolberg S, Reinartz R, Betz RC, Ruzicka T, Hennies HC, Kruse R, Nöthen MM: Genome-wide scan and fine-mapping linkage study of androgenetic alopecia reveals a locus on chromosome 3q26". Am J Hum Genet. 2008, 82 (3): 737-743. 10.1016/j.ajhg.2007.11.014. doi:10.1016/j.ajhg.2007.11.014 doi:10.1016%2Fj.ajhg.2007.11.014PubMedPubMed CentralView ArticleGoogle Scholar
- Shimomura Y, Wajid M, Ishii Y, Shapirob Y, Petukhova L, Derek G, Christiano AM: Disruption of P2RY5, an orphan G protein–coupled receptor, underlies autosomal recessive woolly hair. Nat Genet. 2008, 40 (3): 335-339. 10.1038/ng.100. doi:10.1038/ng.100 doi:10.1038%2Fng.100. PMID 18297072PubMedView ArticleGoogle Scholar
- Petukhova L, Sousajr E, Martinezmir A, Vitebsky A, Dos Santos LG, Shapiro L, Haynes C, Gordon D, Shimomura Y, Christiano AM: Genome-wide linkage analysis of an autosomal recessive hypotrichosis identifies a novel P2RY5 mutation. Genomics. 2008, doi:10.1016/j.ygeno.2008.06.009 doi:10.1016%2Fj.ygeno.2008.06.009. PMID 18692127 (5): 273-278. doi:10.1016/j.ygeno.2008.06.009 doi:10.1016%2Fj.ygeno.2008.06.009 . PMID 18692127View ArticleGoogle Scholar
- Pasternack SM, von Kügelgen I, Aboud KA, Lee YA, Rüschendorf F, Voss K, Hillmer AM, Molderings GJ, Franz T, Ramirez A, Nürnberg P, Nöthen MM, Betz RC: G protein-coupled receptor P2Y5 and its ligand LPA are involved in maintenance of human hair growth. Nat Genet. 2008, 40 (3): 329-334. 10.1038/ng.84.PubMedView ArticleGoogle Scholar
- Stárka L, Cermáková I, Dusková M, Hill M, Dolezal M, Polácek V: Hormonal profile of men with premature balding. Exp Clin Endocrinol Diabetes. 2004, 112 (1): 24-28. doi:10.1055/s-2004-815723 doi:10.1055%2Fs-2004-815723 . PMID 14758568PubMedView ArticleGoogle Scholar
- Denmark-Wahnefried W, Lesko SM, Conaway MR, Robertson CN, Clark RV, Lobaugh B, Mathias BJ, Strigo TS, Paulson DF: Serum androgens: associations with prostate cancer risk and hair patterning. J Androl. 1997, 18 (5): 495-500.Google Scholar
- Ellis JA, Panagiotopoulos S, Akdeniz A, Jerums G, Harrap SB: Androgenic correlates of genetic variation in the gene encoding 5α-reductase type 1. J Hum Genet. 2005, 50 (10): 534-537. 10.1007/s10038-005-0289-x.PubMedView ArticleGoogle Scholar
- de Sousa IC VD, Tosti A: New investigational drugs for androgenetic alopecia. Expert Opin Invest Drugs. 2013, 22 (5): 573-589. 10.1517/13543784.2013.784743.View ArticleGoogle Scholar
- Drake LA, Dinehart SM, Farmer ER, Goltz RW, Graham GF, Hordinsky MK, Lewis CW, Pariser DM, Webster SB, Whitaker DC, Butler B, Lowery BJ, Price VH, Baden H, DeVillez RL, Olsen E, Shupack JL, American Academy of Dermatology: Guidelines of care for androgenetic alopecia. J Am Acad Dermatol. 1996, 35 (3 Pt 1): 465-469.PubMedGoogle Scholar
- Ota Y, Iwamoto S, Kumagai N, Arakawa Y: Spontaneous two-photon emission from a single quantum dot. Phys Rev Lett. 2011, 107 (23): 233602-PubMedView ArticleGoogle Scholar
- Lim CS, Masanta G, Kim HJ, Han JH, Kim HM, Cho BR: Ratiometric detection of mitochondrial thiols with a two-photon fluorescent probe. J Am Chem Soc. 2011, 133 (29): 11132-11135. 10.1021/ja205081s.PubMedView ArticleGoogle Scholar
- Karu TI, Pyatibrat LV, Afanasyeva NI: A novel mitochondrial signaling pathway activated by visible-to-near infrared radiation. Photochem Photobiol. 2004, 80 (2): 366-372. 10.1562/2004-03-25-RA-123.1.PubMedView ArticleGoogle Scholar
- Heger M, Heemskerk AA, van der Zwan G: Absence of 633-nm laser irradiation-induced effects on glucose phosphorylation by hexokinase. J Photochem Photobiol B. 2010, 98 (3): 216-222. 10.1016/j.jphotobiol.2010.01.004.PubMedView ArticleGoogle Scholar
- Shorter K, Farjo NP, Picksley SM, Randall VA: Human hair follicles contain two forms of ATP-sensitive potassium channels, only one of which is sensitive to minoxidil. FASEB J. 2008, 22 (6): 1725-173. 10.1096/fj.07-099424.PubMedView ArticleGoogle Scholar
- Vidali S, Knuever J, Lerchner J, Giesen M, Bíró T, Klinger M, Kofler B, Funk W, Poeggeler B, Paus R: Hypothalamic-pituitary-thyroid axis hormones stimulate mitochondrial function and biogenesis in human hair follicles. J Invest Dermatol. 2014, 134 (1): 33-42. 10.1038/jid.2013.286.PubMedView ArticleGoogle Scholar
- Rossi A, Cantisani C, Scarnò M, Trucchia A, Fortuna MC, Calvieri S: Finasteride, 1 mg daily administration on male androgenetic alopecia in different age groups: 10-year follow-up. Dermatol Ther. 2011, 24 (4): 455-461. 10.1111/j.1529-8019.2011.01441.x. doi:10.1111/j.1529-8019.2011.01441.xPubMedView ArticleGoogle Scholar
- Kritsky MS, Telegina TA, Vechtomova YL, Kolesnikov MP, Lyudnikova TA, Golub OA: Excited flavin and pterin coenzyme molecules in evolution. Biochemistry (Mosc). 2011, 75 (10): 1200-1216.View ArticleGoogle Scholar
- Karu TI, Pyatibrat LV, Kalendo GS: Cell attachment to extracellular matrices is modulated by pulsed radiation at 820 nm and chemicals that modify the activity of enzymes in the plasma membrane. Lasers Surg Med. 2001, 29 (3): 274-281. 10.1002/lsm.1119.PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.